LFS-P532019-01-29T13:16:56+00:00

“In particular, novel immunotherapies with vaccines, checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, monoclonal antibodies and IMiDs, alone and especially in combination, can enhance host anti-MM immunity, even in high-risk MM,” they wrote. “These and other novel strategies are necessary to treat patients with unfavorable prognostic factors, such as chromosome 17p deletions and/or TP53 mutations, and to target specific tumoral abnormalities in subsets of patients with MM |
Bron: http://www.medpagetoday.com/resource-center/mulitple-myeloma-management/Novel-Targets/a/54618

Analysis of p73 and p53 gene deletions in multiple myeloma
http://www.nature.com/leu/journal/v13/n12/pdf/2401609a.pdf?origin=publication_detail

TP53 17p13 deletion by FISH
http://www.mplnet.com/tests/p53-deletion-17p13-1

Presence of a p53 deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy
https://www.researchgate.net/publication/13605456_Presence_of_a_p53_deletion_in_patients_with_multiple_myeloma_predicts_for_short_survival_after_conventional-dose_chemotherapy